‘We’re Still In The EU!’ UK MHRA Insists As Brexit Talks Move Into Phase 2
Executive Summary
The UK MHRA says it plans to continue playing a full part in the EU regulatory network as Brexit negotiations continue, while a task force at the EU industry body EFPIA has discussed contingency planning and other issues.
You may also be interested in...
UK MHRA ‘Pushback’ Against Efforts To Sideline It From EU Processes
The EMA says the UK is continuing to bid for EU regulatory work as the Brexit date of March 29, 2019 draws nearer. The head of the BioIndustry Association says this is something of a “pushback” against efforts to squeeze the UK out of its EU regulatory role in preparation for Brexit.
Change Your RMS In Just Days – And For Free, Ireland’s Brexit Guidance Says
Ireland’s Health Products Regulatory Authority has moved quickly in issuing guidance for drug companies on making Brexit-related changes.
Massive Reallocation of UK Rapporteurships Likely As EMA Plans For Future; UK’s Interim Role Uncertain
If Brexit means the UK no longer plays a part in the EU drug regulatory system, responsibility for the ongoing oversight of almost one in four of all the human medicines that have ever been approved under the centralized procedure will have to be reassigned from the UK to other member states. What Brexit means for the UK’s role as a key player in the regulatory system in the meantime is the subject of speculation.